Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Marrero, Louisiana Clinical Trials

A listing of Marrero, Louisiana clinical trials actively recruiting patient volunteers.

RESULTS

Found (30) clinical trials

A Study on Safety Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)

The total study duration will be up to 10 weeks that includes a 6-week treatment period with dose escalation every 2 weeks.

Phase

1.62 miles

Learn More »

Hyperbaric Oxygen Therapy and SPECT Brain Imaging in Cerebral Decompression Illness

SPECT brain imaging has been shown to be the most sensitive imaging modality for cerebral decompression illness. This study is a retrospective review of the PI's experience using SPECT brain imaging in the diagnosis and treatment of all phases of cerebral decompression illness over the past two decades. The purpose ...

Phase

2.8 miles

Learn More »

Oxygen Toxicity of HBOT in Chronic Brain Injury

The study is a retrospective review of the author's experience treating chronic brain injury with HBOT, supplemented by cases communicated to the author, who developed untoward effects during or after their HBOT. The object of the study was to affirm or refute the author's general impression that there was an ...

Phase

2.8 miles

Learn More »

Hyperbaric Oxygen Therapy and SPECT Brain Imaging in Traumatic Brain Injury

The study is a retrospective chart review of patients with chronic neurological, emotional, social, and cognitive deficits from mild, moderate, or severe traumatic brain injury who underwent SPECT brain imaging as part of their evaluation and treatment with hyperbaric oxygen therapy in my practice over the last two decades. The ...

Phase

2.8 miles

Learn More »

30-Day Trial of Oral Valtrex or Valtrex Plus Aspirin on Shedding of HSV DNA in Tears and Saliva of Volunteers

Published studies have shown that treatment with oral acyclovir reduced clinical recurrences of ocular herpetic keratitis by about 40-50 %8, and treatment with valacyclovir, a more soluble prodrug of acyclovir, reduced the risk of transmission of genital herpes9, 10, 11. For this study, we will use the dose of valacyclovir ...

Phase

3.79 miles

Learn More »

AMG 176 First in Human Trial in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia

This is a Phase 1, first-in-human, multicenter; non-randomized, open-label and dose-exploration study of AMG 176 administered IV in subjects with relapsed or refractory multiple myeloma and subjects with relapsed or refractory acute myeloid leukemia The study will be conducted in four parts.

Phase

4.39 miles

Learn More »

A Safety Study of SGN-LIV1A in Breast Cancer Patients

This study will examine the safety and tolerability of SGN-LIV1A (ladiratuzumab vedotin) in patients with metastatic breast cancer. SGN-LIV1A will be given every 3 weeks alone or in combination with trastuzumab.

Phase

4.48 miles

Learn More »

Pembrolizumab in Treating Patients With HIV and Relapsed Refractory or Disseminated Malignant Neoplasms

PRIMARY OBJECTIVES: I. To assess the safety and tolerability of MK-3475 (pembrolizumab) in HIV-infected patients on effective antiretroviral therapy and with relapsed/refractory or disseminated acquired immune deficiency syndrome (AIDS)-defining or non-AIDS defining malignancy. II. To assess the safety and feasibility of MK-3475 (pembrolizumab) administration as first systemic therapy for HIV ...

Phase

4.48 miles

Learn More »

Food-Effect Bioavailability Study of AQ-13 a Candidate Antimalarial

This is a 2-stage, randomized crossover study of a 2100 mg AQ-13 dose in healthy volunteers. Fourteen healthy volunteers will be randomized to receive the drug either on an empty stomach or after a standard fatty meal under continuous monitoring in the hospital. After a washout period of 8 weeks, ...

Phase

4.48 miles

Learn More »

Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)

PRIMARY OBJECTIVES: I. To determine a safe dose of niraparib when combined with radium Ra 223 dichloride (radium-223) in patients with metastatic castrate-resistant prostate cancer (mCRPC) that have and have not received prior chemotherapy. SECONDARY OBJECTIVES: I. To determine the proportion of subjects with 50% prostate-specific antigen (PSA) reduction from ...

Phase

4.48 miles

Learn More »